dc.contributor.author | Nilsen, Dennis WT | |
dc.contributor.author | Aarsetøy, Reidun | |
dc.contributor.author | Pønitz, Volker | |
dc.contributor.author | Ueland, Thor | |
dc.contributor.author | Aukrust, Pål | |
dc.contributor.author | Michelsen, Annika Elisabet | |
dc.contributor.author | Andersen, Trygve Brugger | |
dc.contributor.author | Staines, Harry | |
dc.contributor.author | Grundt, Heidi | |
dc.date.accessioned | 2024-10-30T10:11:48Z | |
dc.date.available | 2024-10-30T10:11:48Z | |
dc.date.issued | 2024-02-25 | |
dc.description.abstract | Introduction: SERPINA3 is an acute phase protein triggered by inflammation. It is upregulated after an acute myocardial infarction (AMI). Data on its long-term prognostic value in MI patients are scarce. We aimed to assess the utility of SERPINA3 as a prognostic marker in patients hospitalized for chest pain of suspected coronary origin.
Methods: A total of 871 consecutive patients, 386 diagnosed with AMI, were included. Stepwise Cox regression models, applying continuous loge-transformed values, were fitted for the biomarker with all-cause mortality and cardiac death within 2-years or all-cause mortality within median 7 years as dependent variables. An analysis of MI and stroke, and combined endpoints, respectively, was added. The hazard ratio (HR) (95% CI) was assessed in a univariate and multivariable model.
Results: Plasma samples from 847 patients were available. By 2 years follow-up, 138 (15.8%) patients had died, of which 86 were cardiac deaths. The univariate analysis showed a significant association between SERPINA3 and all-cause mortality [HR 1.41 (95% 1.19-1.68), p<0.001], but not for cardiac death. Associations after adjustment were non-significant. By 7 years follow-up, 332 (38.1%) patients had died. SERPINA3 was independently associated with all-cause mortality from the third year onwards. The HR was 1.14 (95% CI, 1.02-1.28), p=0.022. Similar results applied to combined endpoints, but not for MI and stroke, respectively. The prognostic value of SERPINA3 was limited to non-AMI patients. No independent associations were noted among AMI patients.
Conclusions: SERPINA3 predicts long-term all-cause mortality, but failed to predict outcome in AMI patients. | en_US |
dc.identifier.citation | Nilsen DW, Aarsetøy R, Pønitz V, Ueland T, Aukrust P, Michelsen A, Andersen T, Staines H, Grundt H. α1-Antichymotrypsin Complex (SERPINA3) Is an Independent Predictor of All-Cause but Not Cardiovascular Mortality in Patients Hospitalized for Chest Pain of Suspected Coronary Origin. Cardiology. 2024;149(4):338-346 | en_US |
dc.identifier.cristinID | FRIDAID 2272868 | |
dc.identifier.doi | 10.1159/000537919 | |
dc.identifier.issn | 0008-6312 | |
dc.identifier.issn | 1421-9751 | |
dc.identifier.uri | https://hdl.handle.net/10037/35372 | |
dc.language.iso | eng | en_US |
dc.publisher | Karger | en_US |
dc.relation.journal | Cardiology | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2024 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.subject | VDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771 | en_US |
dc.subject | VDP::Midical sciences: 700::Clinical medical sciences: 750::Cardiology: 771 | en_US |
dc.subject | VDP::Medisinske fag: 700::Klinisk medisinske fag: 750 | en_US |
dc.subject | VDP::Midical sciences: 700::Clinical medical sciences: 750 | en_US |
dc.subject | Biomarkører / Biomarkers | en_US |
dc.title | α1-Antichymotrypsin Complex (SERPINA3) Is an Independent Predictor of All-Cause but Not Cardiovascular Mortality in Patients Hospitalized for Chest Pain of Suspected Coronary Origin | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |